Search Results - Frederic Triebel

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma by Christian Mueller, Andrew Haydon, Victoria Atkinson, Prashanth Prithviraj, Frederic Triebel, Chrystelle Brignone, Adnan Khattak, Melissa Eastgate, Amitesh Roy

Get full text

948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC by Christian Mueller, Frederik Marmé, Luc Dirix, Frederic Triebel, Hans Wildiers, Peter Vuylsteke, Chrystelle Brignone, Jens Huober, Sherko Kümmel, Anne Armstrong, Eveline De Cuypere, Florence Dalenc, Steven Chan, Carolina Pia Schröder, Jean-Philippe Jacquin, Etienne Brain, Zsuzsanna Pápai

595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab by Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1... by Matthew G. Krebs, MD, Martin Forster, MD, PhD, Margarita Majem, MD, PhD, Julio Peguero, MD, Wade Iams, MD, Tim Clay, MD, Patricia Roxburgh, MD, PhD, Bernard Doger, MD, PhD, Pawan Bajaj, MD, Andres Barba, MD, Suvini Perera, MS, Christian Mueller, MS, Frédéric Triebel, MD, PhD

Get full text